Abstract: VS-4718, also known as PND-1186, is an oral, highly selective, and reversible small-molecule inhibitor of focal adhesion kinase (FAK). FAK is a non-receptor tyrosine kinase that is frequently overexpressed in various solid tumors, including pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC), where it drives tumor progression, metastasis, and therapy resistance. This literature review synthesizes current research on VS-4718, highlighting its pharmacological activity, molecular mechanisms, and therapeutic potential. In PDAC, VS-4718 demonstrates significant cytotoxicity, radiosensitizes tumor cells in the presence of stromal extracellular matrix (ECM), and enhances the efficacy of oncolytic virotherapy. In TNBC, it effectively blocks cell migration and growth stimulated by estrogenic and insulin-like growth factor (IGF) signaling. Mechanistically, VS-4718 inhibits FAK autophosphorylation at Tyr-397, impairs DNA repair, induces cell cycle arrest, and disrupts critical downstream signaling axes, including STAT3 and YAP/TEAD. Despite its promising preclinical profile, VS-4718 exhibits modest efficacy as a monotherapy in clinical settings and displays variable efficacy across different cell lines. Future perspectives emphasize the necessity of combination therapies, the identification of predictive biomarkers, and the optimization of treatment regimens to maximize its clinical utility in solid tumor oncology.
1. Introduction
Focal adhesion kinase (FAK), encoded by the PTK2 gene, is a scaffolding non-receptor tyrosine kinase that plays a pivotal role in cellular processes such as cell-extracellular matrix (ECM) interactions, motility, anchorage-independent growth, proliferation, and survival [1]. Upon activation by integrin-ECM engagement or G-protein coupled receptors (GPCRs), FAK undergoes autophosphorylation at the Tyr-397 (Y397) residue, creating a binding site for various signaling molecules [3]. FAK is frequently overexpressed in highly aggressive solid tumors, including pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC), where its elevated expression correlates with poor clinical outcomes, increased stem cell populations, and resistance to standard therapies [1][4].
VS-4718 (previously known as PND-1186) is an orally available, highly selective, and reversible small-molecule FAK tyrosine kinase inhibitor (TKI) [1]. It has emerged as a promising targeted therapeutic agent in solid tumor research. This review explores the pharmacological activity, molecular mechanisms, limitations, and future therapeutic strategies involving VS-4718 based on recent preclinical studies.
2. Pharmacological Activity
VS-4718 exhibits potent anti-tumor activity across multiple solid tumor models, particularly in PDAC and TNBC, by targeting both the tumor cells and the surrounding microenvironment.
Pancreatic Ductal Adenocarcinoma (PDAC): VS-4718 demonstrates dose-dependent cytotoxicity across a panel of PDAC cell lines, with IC50 values ranging from low to moderate micromolar concentrations (e.g., 1.23 µM in PSN-1, 3.69 µM in Beta-TC-3, and up to 60.85 µM in the more resistant MIA PaCa-2 line) [1][2]. Beyond direct cytotoxicity, VS-4718 acts as a potent radiosensitizer. In vitro, it significantly enhances the radiosensitivity of PDAC cells, an effect that is highly dependent on the presence of ECM-producing pancreatic stellate cells (PSCs) or a collagen I matrix [1]. In three-dimensional (3D) multicellular tumor spheroid models comprising both cancer and stellate cells, the combination of VS-4718 and radiotherapy effectively inhibits tumor aggregate growth at significantly lower radiation doses compared to radiation alone [1]. Furthermore, VS-4718 targets the tumor stroma by reducing the viability of stellate cells and markedly decreasing their collagen production [1]. VS-4718 has also been shown to enhance the oncolytic activity of the coxsackievirus B3 (CVB3) strain PD-H, yielding synergistic or additive cytotoxic effects in specific PDAC cell lines [2].
Triple-Negative Breast Cancer (TNBC): In TNBC, VS-4718 effectively counteracts tumor progression and metastatic potential. It abolishes the colony formation capability and spheroid expansion induced by Insulin-like Growth Factor-1 (IGF-1) [4]. Additionally, VS-4718 prevents the migration and invasiveness of TNBC cells triggered by the activation of the G-protein coupled estrogen receptor (GPER) [3].
3. Molecular Mechanism of Action
The primary mechanism of action of VS-4718 is the selective inhibition of FAK kinase activity by blocking its autophosphorylation at the Tyr-397 residue [1][2]. It is also noted to inhibit PYK2, another kinase involved in tumor cell proliferation [2]. This primary inhibition cascades into several critical downstream effects:
DNA Damage Response and Cell Cycle Arrest: In PDAC models, FAK inhibition by VS-4718 impairs DNA repair mechanisms following radiotherapy. This is evidenced by a significant increase in residual γ-H2AX foci in cancer cells 24 hours post-irradiation. Furthermore, VS-4718 exposure arrests the cell cycle in the highly radiosensitive G2/M phase, thereby improving overall radiation sensitivity [1].
Disruption of the GPER/STAT3 Axis: In TNBC, estrogenic signaling via GPER rapidly stimulates FAK activation. VS-4718 intercepts this pathway, preventing the downstream nuclear accumulation of Signal Transducer and Activator of Transcription 3 (STAT3). Consequently, VS-4718 reduces the expression of GPER/STAT3 target genes, including c-FOS, EGR1, and CTGF, which are critical for cell migration and invasion [3].
Inhibition of the IGF-1R/YAP Axis: The IGF-1/IGF-1R system promotes TNBC growth by activating FAK. VS-4718 blocks this IGF-1-induced FAK phosphorylation, which in turn prevents the nuclear translocation and activation of YAP (Yes-associated protein), a key transcriptional co-activator of the Hippo pathway. By inhibiting FAK, VS-4718 suppresses YAP/TEAD-dependent transcriptional activity and downregulates canonical target genes such as CTGF and Cyr61. Additionally, VS-4718 prevents IGF-1-induced AKT phosphorylation, indicating its role in disrupting the broader PI3K/AKT survival cascade [4].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail specific structural modifications and their corresponding effects on the biological activity of VS-4718, the compound is chemically classified as a highly selective, reversible small-molecule tyrosine kinase inhibitor. At micromolar concentrations, its activity is highly specific to FAK and FLT3 (with the latter expressed only in cells of hematopoietic origin), as well as PYK2 [1][2]. Its ability to specifically target the autophosphorylation site Tyr-397 is central to its pharmacological efficacy across various solid tumor models [2].
5. Current Limitations
Despite robust preclinical data, the clinical translation of VS-4718 and other FAK inhibitors faces several limitations:
- Modest Monotherapy Efficacy: In clinical trials, FAK inhibitors have demonstrated limited efficacy as monotherapies, typically resulting in disease stabilization in only a small subset of patients rather than significant tumor regression [1][2].
- Variable Cellular Sensitivity: Tumor cell lines exhibit heterogeneous responses to VS-4718. For instance, while PDAC cell lines like Capan-1 and PSN-1 are highly sensitive, others like MIA PaCa-2 display marked resistance, requiring significantly higher doses to achieve cytotoxicity [1][2].
- Antagonism in Virotherapy: While VS-4718 can enhance oncolytic virotherapy, it also dose-dependently inhibits the replication of oncolytic viruses (such as CVB3 PD-H). At high concentrations, this suppression of viral replication can negate the benefits of the combination, leading to antagonistic rather than synergistic effects [2].
6. Future Perspectives
The future of VS-4718 in solid tumor research lies predominantly in rational combination strategies and precision medicine:
- Combination Therapies: Because FAK inhibition alone is often insufficient, combining VS-4718 with other modalities is crucial. Promising combinations include radiotherapy (to exploit G2/M arrest and impaired DNA repair) [1], targeted agents like IGF-1R inhibitors (e.g., OSI-906) [4], immune checkpoint inhibitors, and optimized oncolytic virotherapy [2].
- Regimen Optimization: To overcome the antagonistic effects observed with oncolytic viruses, future studies must focus on optimizing treatment regimens, such as employing sequential rather than simultaneous administration of VS-4718 and viral agents [2].
- Predictive Biomarkers: The variable sensitivity among tumor profiles underscores the urgent need for predictive biomarkers. Identifying patients who are most likely to respond to FAK inhibition will prevent unnecessary treatments, minimize therapeutic failure, and improve overall clinical outcomes [2].
